Navion Capital II Proposes Qualifying Transaction with Maple Brain Healthcare

Navion Capital II Inc. has announced the execution of a non-binding letter of intent with Maple Brain Healthcare Inc. The Proposed Transaction involves a reverse takeover, subject to TSXV approval, with Maple Brain's shareholders acquiring all of Navion Capital's common shares. Upon completion, the resulting entity will operate under the business name of Maple Brain, pending final approvals.

Maple Brain is a medical device software company focusing on AI solutions for clinical workflows. The firm is progressing through a Health Canada clearance process for its AI-supported neurology software. This software aims to support clinical teams while maintaining safety and compliance.

To fund the Proposed Transaction and business growth, Maple Brain plans to raise a minimum of $1,500,000 through a SAFE financing, adhering to TSXV policies. Subsequently, the boards and management teams will be restructured to include members from both companies.

TSXV trading for Navion Capital is currently halted and is expected to resume post-transaction. Completion is contingent on various approvals, including regulatory and shareholder agreements.